Bermekimab

From WikiMD's Wellnesspedia


Bermekimab[1] (MABp1, trade name Xilonix) is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A).[2] As of March 2017, bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer[3] and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis.[4]

Bermekimab is being developed by XBiotech Inc.[5]

References[edit | edit source]

  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Bermekimab, American Medical Association.
  2. "A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (XCITE)". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 3 March 2017.
  3. "A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 18 December 2018.
  4. "Xilonix™ True Human™ monoclonal antibody by Xbiotech oncology". www.xbiotech.com. XBiotech. Retrieved 3 March 2017.


Bermekimab Resources

Find a healthcare provider anywhere in the world quickly and easily!

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD